Status:
COMPLETED
Efficacy of Remicade in the Treatment of Active Rheumatoid Arthritis Despite Methotrexate (Study P03027)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Arthritis, Rheumatoid
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
This is an open-label program of Remicade in the treatment of patients with active rheumatoid arthritis (RA) despite treatment with methotrexate (MTX) to determine the onset of efficacy of infliximab.
Eligibility Criteria
Inclusion
- Men and women, \>=18 to \<=75 years of age.
- Diagnosis of RA according to the revised 1987 criteria of the American Rheumatism Association (Arnett et al., 1988). The disease should have been diagnosed at least 6 months prior to Screening.
- Patients have active disease, in the opinion of the physician, despite the concomitant use of DMARDS. Evidence of active disease may include any of the following:
- 6 or more swollen or tender joints; and 2 of the following
- Morning stiffness \>45 minutes
- C-reactive protein \>2.0 mg/L
- ESR \>28 mm/h
- Patients must have been using oral or parenteral MTX for at least 2 months with no break(s) in treatment of more than 2 weeks total during this period. Patients must have been on a stable dose of \>=7.5 mg/wk (IM, SQ, PO) for at least 8 weeks prior to Screening.
- Men and women of childbearing potential must be using adequate birth control measures (abstinence, oral contraceptives, IUD, barrier method with spermicide or, surgical sterilization) and should continue such precautions for 6 months after receiving the last infusion.
- Patients must be on a stable dose of folic acid prophylaxis for at least 4 weeks prior to Screening.
- Patients using oral corticosteroids or NSAIDs, must have been on a stable dose for at least 4 weeks prior to Screening, and must continue during the treatment period. If currently not using corticosteroids or NSAIDs, the patient must have not received corticosteroids or NASIDs for at least 4 weeks prior to Screening.
- Patients must be able to adhere to the program visit schedule and other protocol requirements.
- Patients must be capable of giving informed consent and the consent must have been obtained prior to any screening procedures.
Exclusion
- Pregnant women, nursing mothers or a planned pregnancy within 1.5 years of enrollment
- Patients who are incapacitated, largely or wholly bedridden or confined to a wheelchair, and who have little or no ability for self-care.
- Patients who have any current systemic inflammatory condition with signs and symptoms that might confound the evaluations of benefit from the Remicade therapy, eg, Lyme disease, or a rheumatic disease other than RA.
- Use of DMARDS other than MTX within 4 weeks prior to Screening.
- Use of intra-articular, IM, or IV. corticosteroids (including IM ACTH) within 4 weeks prior to Screening.
- Prior administration any other therapeutic agent targeted at reducing TNF (eg, Etanercept, pentoxifylline, thalidomide or anti-CD4+ antibody) within the previous 6 months.
- Treatment with any investigational drug within the previous 6 months.
- A history of known allergies to murine proteins.
- Serious infections, such as hepatitis, pneumonia, pyelonephritis in the previous 3 months. Less serious infections in the previous 3 months, such as acute upper respiratory tract infection (colds) or uncomplicated urinary tract infection need not be considered exclusions at the discretion of the treating physician.
- History of opportunistic infections such as herpes zoster within 2 months of Screening. Evidence of active CMV, active pneumocystis carinii, drug resistant atypical mycobacterium, etc.
- Documented HIV infection.
- Current signs or symptoms of severe, progressive or uncontrolled renal, hepatic, hematologic, endocrine, pulmonary, cardiac, neurologic or cerebral disease.
- Any currently known malignancy or pre-malignant lesions or any history of malignancy within the past 5 years.
- Patients with alcoholism, alcoholic liver disease, or other chronic liver disease.
- Patients with a positive PPD within 3 months and chest X-Ray suggestive of active TB or a previous exposure to TB.
- Patients with CHF, even if asymptomatic or not requiring medication must be excluded.
Key Trial Info
Start Date :
July 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2004
Estimated Enrollment :
19 Patients enrolled
Trial Details
Trial ID
NCT00794898
Start Date
July 1 2003
End Date
April 1 2004
Last Update
March 28 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.